News

Grace Therapeutics Presents Trial Findings at SVIN Annual Meeting

Grace Therapeutics Presents Trial Findings at SVIN Annual Meeting

Grace Therapeutics Announces Exciting Presentation at SVIN Annual Meeting

Grace Therapeutics, Inc. (NASDAQ: GRCE) has recently shared significant news that their abstract has been accepted for a special presentation at the annual meeting of the Society of Vascular and Interventional Neurology (SVIN). This prestigious event will take place over several days, with a focus on innovative research and advancements in neurology.

Overview of the GTx-104 Presentation

At this year's meeting, an oral presentation will highlight the results of the Company's pivotal Phase 3 STRIVE-ON Safety Trial, which investigated the safety and tolerability of GTx-104, a new injectable formulation of nimodipine. This product is specifically aimed at treating patients with aneurysmal subarachnoid hemorrhage (aSAH).

Importance of aSAH and the STRIVE-ON Trial

Aneurysmal subarachnoid hemorrhage is a serious and relatively rare type of stroke caused by the rupture of an aneurysm in the brain. It leads to bleeding in the subarachnoid space, which can result in significant complications and is associated with high mortality rates. The ongoing STRIVE-ON trial has aimed to evaluate how GTx-104 performs in comparison to traditional oral nimodipine, making this presentation a critical moment for patients and healthcare professionals.

Leading Medical Expert on Trial Findings

Renowned neurologist Thomas P. Bleck, MD, who serves at the Northwestern University Feinberg School of Medicine, will deliver the findings of this important trial. Scheduled for November 21, the presentation promises to offer new insights that could guide the future of treatment for aSAH.

Presentation Logistics

The session is set for November 21, 2025, where viewers can expect a detailed overview of the abstract titled, Safety and Tolerability of GTx-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage: a Prospective, Randomized Trial. This represents a significant step forward in addressing a crucial healthcare challenge.

About GTx-104 and its Development

GTx-104 is an innovative solution designed for intravenous (IV) infusion. Utilizing advanced nanoparticle technology, it improves the solubility of nimodipine, a drug essential for treating patients with aSAH. This capability allows healthcare providers to administer the drug more effectively in a clinical setting, especially among patients unable to take oral medications. The development of GTx-104 has shown promising results, being well-tolerated in previous studies involving over 200 participants.

Clinical Benefits of GTx-104

This novel formulation is expected to lessen the risks associated with oral dosing, such as dosing errors and variable absorption rates. GTx-104's delivery mechanism can help manage complications like hypotension effectively, making it a potentially transformative option for critically ill patients.

About Grace Therapeutics, Inc.

Grace Therapeutics is a biopharma company focused on bringing innovative therapies to patients suffering from rare and orphan diseases. With a robust pipeline and several granted orphan drug designations, the Company is committed to leveraging its unique drug delivery technologies to enhance treatment outcomes and provide better options for patient care.

Contact Grace Therapeutics for More Information

For more insights into their work and innovations, you can reach out to Grace Therapeutics directly at:

Grace Therapeutics Contact:
Prashant Kohli
Chief Executive Officer
Tel: 450-686-4555
Email: info@gracetx.com
Website: www.gracetx.com

Frequently Asked Questions

What is GTx-104?

GTx-104 is a clinical-stage injectable formulation of nimodipine designed for IV administration in aneurysmal subarachnoid hemorrhage patients.

What is the significance of the STRIVE-ON trial?

The STRIVE-ON trial is crucial for determining the safety and efficacy of GTx-104 compared to standard oral medications for treating aSAH.

Who is presenting the trial results?

Dr. Thomas P. Bleck, a prominent neurologist, will present the trial results at the SVIN annual meeting.

When and where will the presentation take place?

The oral presentation will be held on November 21, 2025, at the SVIN annual meeting.

How does GTx-104 improve patient care?

GTx-104 can provide a more reliable and effective method for administering nimodipine, potentially leading to better treatment outcomes for patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 70

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 10

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 6

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 228

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 56

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 91

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading

Top 5 Most Recently Viewed Articles

Embracing Harmony and Cooperation in Today's World

Updated Category News Views 99

Understanding the Essence of Hehe Culture The concept of "Hehe" in Chinese culture symbolizes harmony, peace, and cooperation, deeply embedded in the collective mindset. This philosophy, with roots extending over thousands of years, emphasizes living in balance not only with one another but also with nature and oneself. The teachings of Hehe are particularly significant...

Continue Reading
Current Trends in Mortgage Rates and Home Buying Activity

Updated Category News Views 184

The average rate for a 30-year fixed-rate mortgage dropped to 6.08% in 2024, hitting its lowest point in two years. This slight decrease from 6.09% the previous week caught the eye of potential home buyers and homeowners considering refinancing. In contrast, the average rate for a 15-year mortgage ticked up by a single basis point to reach 5.16%. These small fluctuations...

Continue Reading
Mueller Water Products Engages at 2024 Baird Industrial Conference

Updated Category News Views 195

Mueller Water Products to Engage in the Baird Industrial Conference Mueller Water Products, Inc. (NYSE: MWA), headquartered in Atlanta, is set to participate in the Baird 2024 Global Industrial Conference. This prestigious event will take place in a vibrant city known for its industrial drive and innovation. Mueller’s management team is looking forward to sharing...

Continue Reading
SANY Showcases Advanced Eco-Friendly Solutions at bauma

Updated Category News Views 389

SANY Showcases Advanced Eco-Friendly Solutions at bauma The 34th bauma, recognized as the world's leading trade fair for construction machinery, recently wrapped up in Munich. This year's theme was "The World of Efficiency, Your Partner to Create the Best", and SANY Group, in collaboration with Putzmeister, put forth an impressive display of cutting-edge technology and...

Continue Reading
Orbit International Corp Completes $1 Million Power Supply Order

Updated Category News Views 182

Orbit International Corp Secures Major Follow-On Order Orbit International Corp. (OTCID Basic Market: ORBT), a prominent player in electronic manufacturing and software solutions, has announced the receipt of a new order valued at approximately $1,000,000. This order, secured by its Orbit Power Group (OPG), pertains to a commercial power supply that is utilized in...

Continue Reading